Emerging Opportunities in Angiogenesis Inhibitors and Stimulators Market with Current Trends Analysis

Angiogenesis is a physiological process that is associated withthe formation of new blood vessel from existing blood vessels. Angiogenesis process is commonly categorized into two types namely sprouting angiogenesis and intussusceptive angiogenesis. Sprouting angiogenesis is a fundamental mechanism of vessel growth in which formation of new blood vessel is regulated by sequential steps. Intussusceptive angiogenesis (also called as splitting angiogenesis) is referred where new blood vessel is created by internal division of an existing blood vessel.

Report Overview and TOC @ https://www.transparencymarketresearch.com/angiogenesis-inhibitors-stimulators.html 

In contrast to sprouting angiogenesis, intussusceptive do not need local endothelial cell proliferation. Angiogenesis is mainly associated with the diverse set of conditions such as age related macular degradation, rheumatoid arthritis, cancer and psoriasis.The main focus of angiogenesis therapy is to shrink the existing tumor by aninhibitor or to meet the demand of under perfused region through generating new vessels by angiogenesis stimulator. Avastin (bevacizumab), Gleevec, Tarceva and Iressa are some of the largest selling angiogenesis inhibitor drugs worldwide.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1108

Research and development activitiesfor the development of novel angiogenesis drugs for cancer treatment is the highest.Thus, increasing number of cancer cases will drive the growth of this market during the forecast period. According to World Health Organization, approximately 8.2 million deaths are reported in the year of 2012 due to cancer. Also it is predicted that, the annual cancer cases are expected rise from14 million to 22 million in next two decades. In addition, National Cancer Institute states that there are approximately 1,660,290 cases reported in the United States in 2013.Technological advancement will further boost the growth of angiogenesis inhibitor and stimulatorsmarket.For example, research in angiogenesis has enabled identification of several angiogenesis agonist and antagonist. However, high cost of these drugs will restrain the growth of this market.

For Specific and Customized requirements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1108

Geographically, North America represents the largest market, followed by Europe for angiogenesis inhibitors and stimulatorsdue to large patient base and rise in treatment seeking population in these regions. The market of angiogenesis inhibitors and stimulators in Asia-Pacific countries such as India and China, South East Asian countries holds a strong growth as there is a rise in total number of newly diagnosed patient population of cancer in this region. According to World Health Organization, 60% of the world’s total annual cases of cancer occur in Africa, Asia and South America. Some of the key players in the Angiogenesis Inhibitors and Stimulators market comprises Abbott Laboratories, Adnexus Therapeutics, Inc., F. Hoffman-La Roche, Ltd., Genentech, Inc., Amgen, Inc., AstraZeneca Plc., Novartis AG, Pfizer, Inc., Chugai Pharmaceutical Co., Ltd., EntreMed, Inc. and Eyetech, Inc.

Pre Book full report@ https://www.transparencymarketresearch.com/angiogenesis-inhibitors-stimulators.html?secure=NTIxNS41&type=PB

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Transparency Market Research

State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

This release was published on openPR.